Figure S2

(A) BCR-ABL + Imatinib

- 0.25 μM
- 0.5 μM
- 25 μM

exposure time [h]

subG1 [%] at 24h

(B) BCR-ABL + Dasatinib

- 25 nM
- 100 nM

exposure time [h]

subG1 [%] at 24h

(A) BCR-ABL + Imatinib

- 0.25 μM
- 0.5 μM
- 25 μM

exposure time [h]

subG1 [%] at 24h

(B) Ba/F3 parental + Imatinib

- 0.25 μM
- 0.5 μM
- 25 μM

exposure time [h]

subG1 [%] at 24h

(B) Ba/F3 parental + Dasatinib

- 1 nM
- 25 nM
- 100 nM

exposure time [h]

subG1 [%] at 24h
Figure S2: Control cells do not reveal significant cytotoxic effects upon HD-TKI pulse exposure

(A) Ba/F3-BCR-ABL cells (5x10⁴ cells/ml, total volume 2ml) were treated with TKI as indicated for 2h followed by extensive drug wash-out using 2x 2ml PBS. Cells were then re-seeded in 2ml cell culture medium without TKI. Cells exposed to 0.35% DMSO served as controls („0h“). Cells continuously exposed to TKI served as positive controls („24h“). Twenty-four hours after start of TKI exposure the percentage of cells in subG1 phase was measured by flow cytometry after propidium iodide staining. Three independent experiments were performed. Data are presented as mean percentage of cells in subG1 phase +SEM.

(B) Ba/F3 parental cells (5x10⁴ cells/ml, total volume 2ml) were treated for 2h with TKI as indicated followed by thorough drug wash-out using 2x 2ml PBS. Cells were then reseeded in 2ml cell culture medium without TKI. Twenty-four hours after start of TKI exposure the percentage of cells in subG1 phase was measured by flow cytometry after propidium iodide staining. At least three independent experiments were performed and data are presented as mean percentage of cells in subG1 phase +SEM.